Trial · NCT02927769
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
NCT02927769, Phase 2, Completed, Bristol-Myers Squibb; results first posted 2025-02-10
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment. Trials, record NCT02927769. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02927769
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
- NCT number
- NCT02927769
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 72 participants, actual
- Lead sponsor
- Bristol-Myers Squibb
- Conditions
- Hodgkin Disease
- Interventions
- Nivolumab, brentuximab vedotin, bendamustine
- First posted
- 2016-10-07
- Last updated
- 2025-02-10
- Other registries' IDs
- eudract:2016-002347-41
- Results first posted
- 2025-02-10
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1 | From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks). | The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who stopped study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method |
| Primary | Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1 | At 3 years post first dose of study therapy | Event Free Survival (EFS) is the time from the first treatment to the earliest occurrence of composite events including: Disease progression (PD), Failure to achieve complete metabolic response (CMR) after 4 cycles of N+Bv and 2 cycles of Bv+B, Secondary malignancy, Death . PD : Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease CMR: Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale New lesions: No Bone marrow: No FDG-avid disease Participants without an "event" were censored at the last tumor assessment. Those who started subsequent anticancer therapy without a prior "event" were censored at the last tumor assessment prior to or upon starting subsequent therapy. Based on Kaplan-Meier Estimates. |
| Primary | Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2 | From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks) | The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who came off study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method |
| Secondary | Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Blinded Independent Centralized Review (BICR) | From first dose to PMR or CMR within 4 cycles of therapy, or the completion of four cycles of therapy (N+Bv x4) (up to approximately 12 weeks). | Overall response rate (ORR) is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved a best response of complete metabolic response (CMR) or partial metabolic response (PMR). Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response (PMR): * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Participants who came off early for toxicity without CMR or PMR were evaluable. |
| Secondary | Progression Free Survival (PFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) | At 3 years post first dose of study therapy | Progression Free Survival (PFS) is the time from the date of first treatment to the date of first documented disease progression by BICR or death. Progressive Disease (PD): Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease. Participants who neither progressed nor died were censored at the last adequate tumor assessment. Participants who started subsequent anticancer therapy (that is not part of high dose chemotherapy followed by autologous stem cell transplant (HDCT/ASCT) Consolidation Therapy for R2 Cohort) without a prior reported progression or death were censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. Based on Kaplan-Meier Estimates. |
| Secondary | Duration of Response (DOR) by Blinded Independent Centralized Review (BICR) | From first dose until disease progression, start of subsequent anti-cancer therapy, or or death due to any cause (up to approximately 86 months) | Duration of response (DOR) is the time from first complete metabolic response or partial metabolic response (CMR or PMR) to event free survival EFS (Cohort 1)/progression free survival PFS (Cohort 2) event. For participants with no event, DOR was censored on the date of last tumor assessment. Participants who started subsequent anticancer therapy (not part of high-dose chemotherapy followed by autologous stem cell transplant HDCT/ASCT) without a prior reported EFS/PFS event were censored at the last tumor assessment prior to initiation of the subsequent therapy. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response (PMR): * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Based on Kaplan-Meier estimates |
| Secondary | Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Investigator - Cohort 1 | From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks). | The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who come off early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method |
| Secondary | Event-free Survival (EFS) Rate at 3 Years by Investigator - Cohort 1 | At 3 years post first dose of study therapy | Event Free Survival (EFS) is the time from the first treatment to the earliest occurrence of composite events including: Disease progression (PD), Failure to achieve complete metabolic response (CMR) after 4 cycles of N+Bv and 2 cycles of Bv+B, Secondary malignancy, Death . PD : Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease CMR: Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale New lesions: No Bone marrow: No FDG-avid disease Participants without an "event" were censored at the last tumor assessment. Those who started subsequent anticancer therapy without a prior "event" were censored at the last tumor assessment prior to or upon starting subsequent therapy. Based on Kaplan-Meier Estimates. |
| Secondary | Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Investigator - Cohort 2 | From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks) | The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who came off study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method. |
| Secondary | Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Investigator | From first dose to PMR or CMR within 4 cycles of therapy, or the completion of four cycles of therapy (N+Bv x4) (up to approximately 12 weeks). | Overall response rate (ORR) is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieve a best response of complete metabolic response (CMR) or partial metabolic response (PMR). Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response: * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline Participants who came off early for toxicity without CMR or PMR were evaluable. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes17
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1 | From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks). | All treated participants in Cohort 1. Prespecified to be collected for Cohort 1 only. | Percent of participants | NUMBER |
| PRIMARY | Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1 | At 3 years post first dose of study therapy | All treated participants in Cohort 1. Prespecified to be collected for Cohort 1 only. | Percent of participants | NUMBER |
| PRIMARY | Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2 | From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks) | All treated participants in Cohort 2. Prespecified to be collected for Cohort 2 only. | Percent of participants | NUMBER |
| SECONDARY | Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Blinded Independent Centralized Review (BICR) | From first dose to PMR or CMR within 4 cycles of therapy, or the completion of four cycles of therapy (N+Bv x4) (up to approximately 12 weeks). | All treated participants. | Percent of participants | NUMBER |
| SECONDARY | Progression Free Survival (PFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) | At 3 years post first dose of study therapy | All treated participants. | Percent of participants | NUMBER |
| SECONDARY | Duration of Response (DOR) by Blinded Independent Centralized Review (BICR) | From first dose until disease progression, start of subsequent anti-cancer therapy, or or death due to any cause (up to approximately 86 months) | All treated participants with a response of complete metabolic response (CMR) or partial metabolic response (PMR). | Months | MEDIAN |
| SECONDARY | Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Investigator - Cohort 1 | From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks). | All treated participants in Cohort 1. Prespecified to be collected for Cohort 1 only. | Percent of participants | NUMBER |
| SECONDARY | Event-free Survival (EFS) Rate at 3 Years by Investigator - Cohort 1 | At 3 years post first dose of study therapy | All treated participants in Cohort 1. Prespecified to be collected for Cohort 1 only. | Percent of participants | NUMBER |
| SECONDARY | Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Investigator - Cohort 2 | From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks) | All treated participants in Cohort 2. Prespecified to be collected for Cohort 2 only. | Percent of participants | NUMBER |
| SECONDARY | Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Investigator | From first dose to PMR or CMR within 4 cycles of therapy, or the completion of four cycles of therapy (N+Bv x4) (up to approximately 12 weeks). | All treated participants. | Percent of participants | NUMBER |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 outcomesResults by group68
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1 | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | 92.9 | 90% Confidence Interval 79.2 to 98.7 | Percent of participants | |
| Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1 | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | 87.5 | 90% Confidence Interval 70.6 to 95.0 | Percent of participants | |
| Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2 | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse | 88.6 | 90% Confidence Interval 77.6 to 95.4 | Percent of participants | |
| Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Blinded Independent Centralized Review (BICR) | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | 96.4 | 90% Confidence Interval 84.1 to 99.8 | Percent of participants | |
| Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Blinded Independent Centralized Review (BICR) | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse | 93.2 | 90% Confidence Interval 83.3 to 98.1 | Percent of participants | |
| Progression Free Survival (PFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | 95.2 | 90% Confidence Interval 77.7 to 99.1 | Percent of participants | |
| Progression Free Survival (PFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse | 91.1 | 90% Confidence Interval 78.4 to 96.5 | Percent of participants | |
| Duration of Response (DOR) by Blinded Independent Centralized Review (BICR) | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | NA | 95% Confidence Interval NA to NA | Months | |
| Duration of Response (DOR) by Blinded Independent Centralized Review (BICR) | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse | NA | 95% Confidence Interval NA to NA | Months | |
| Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Investigator - Cohort 1 | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | 89.3 | 90% Confidence Interval 74.6 to 97.0 | Percent of participants |
1 to 10 of 68Source ClinicalTrials.gov
See all 68 results by groupParticipant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Induction Phase | STARTED | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | 28 | |
| Induction Phase | STARTED | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse | 44 | |
| Induction Phase | COMPLETED | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | 27 | |
| Induction Phase | COMPLETED | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse | 42 | |
| Induction Phase | NOT COMPLETED | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | 1 | |
| Induction Phase | NOT COMPLETED | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse | 2 | |
| Consolidation Phase | STARTED | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | 22 | |
| Consolidation Phase | STARTED | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse | 32 | |
| Consolidation Phase | COMPLETED | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse | 22 | |
| Consolidation Phase | COMPLETED | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse | 32 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events580
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) | 1 | 22 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) + (Bv + B) | 1 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv) | 6 | 33 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv)+(Bv + B) | 3 | 11 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) | 0 | 22 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) + (Bv + B) | 0 | 6 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv) | 5 | 33 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv)+(Bv + B) | 4 | 11 | |
| other | Leukopenia | Blood and lymphatic system disorders | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) | 0 | 22 | |
| other | Leukopenia | Blood and lymphatic system disorders | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) + (Bv + B) | 1 | 6 |
1 to 10 of 580Source ClinicalTrials.gov
See all 580 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) | 0 | 22 |
| Total, all-cause mortality | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) + (Bv + B) | 0 | 6 |
| Total, all-cause mortality | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv) | 0 | 33 |
| Total, all-cause mortality | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv)+(Bv + B) | 1 | 11 |
| Total, other adverse events | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) | 18 | 22 |
| Total, other adverse events | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) + (Bv + B) | 6 | 6 |
| Total, other adverse events | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv) | 33 | 33 |
| Total, other adverse events | Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv)+(Bv + B) | 11 | 11 |
| Total, serious adverse events | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) | 6 | 22 |
| Total, serious adverse events | Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) + (Bv + B) | 3 | 6 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse vs Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse: The Number of Participants With Serious Adverse Events (SAEs) | Trial comparisons |
Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse vs Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse: The Number of Participants With Adverse Events (AEs) | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02927769
GET https://conductscience.org/api/trials/v1/NCT02927769/results?page=2